促黄体生成素释放激素检测在溴隐亭治疗垂体瘤患者闭经和高泌乳素血症中的价值。

Value of luteinizing hormone-releasing hormone testing in bromocriptine treatment of amenorrhea and hyperprolactinemia in patients with pituitary tumors.

作者信息

Lamberts S W, Docter R, De Jong F H, Birkenhäger J C, Kwa H G

出版信息

Fertil Steril. 1978 Mar;29(3):287-90. doi: 10.1016/s0015-0282(16)43154-7.

Abstract

The results of bromocriptine treatment in 13 patients with radiologically evident pituitary tumors are described. A menorrhea was present in all patients, hyperprolactinemia in 12 of the 13 patients, and acromegaly in 3 patients. Five patients have previously been treated surgically and by radiotherapy because of suprasellar extension of the adenoma. Plasma prolactin levels after one single dose of 2.5 mg of bromocriptine were found to have no predictive value as to the dosage needed for treatment, whereas the plasma gonadotropin response after the administration of luteinizing hormone-releasing hormone appeared to be predictive with respect to the return of ovulation during bromocriptine therapy.

摘要

本文描述了13例经放射学检查证实患有垂体肿瘤患者使用溴隐亭治疗的结果。所有患者均有闭经，13例中有12例存在高泌乳素血症，3例有肢端肥大症。5例患者此前因腺瘤向鞍上扩展接受过手术和放疗。发现单次服用2.5mg溴隐亭后的血浆泌乳素水平对治疗所需剂量无预测价值，而注射促黄体生成素释放激素后血浆促性腺激素反应似乎对溴隐亭治疗期间排卵恢复有预测作用。